VitalConnect

Digital Health · Medical Devices · Cardiac Monitoring

Acquisition

iRhythm completes $237.5M cash-and-stock acquisition of VitalConnect

The deal pushes iRhythm beyond ambulatory patches into hospital and remote monitoring, where rivals have been racing to expand.

• iRhythm Holdings closed its acquisition of VitalConnect for $237.5 million in cash plus up to 423,334 shares, funded from its balance sheet.
• VitalConnect makes wearable biosensors capable of tracking up to 11 physiological parameters, including mobile cardiac telemetry and multi-vitals monitoring for up to 30 days.
• iRhythm also provided VitalConnect $10 million in working capital funding between signing and closing of the deal.
• The acquisition extends iRhythm's reach from ambulatory cardiac monitoring into inpatient, remote and hospital-to-home care settings.
• iRhythm's CEO cited an estimated 27 million people in the U.S. at risk for undiagnosed arrhythmias annually as the market opportunity driving the deal.
• iRhythm plans to issue updated 2026 financial guidance incorporating VitalConnect during its November 5, 2026 earnings call.
• By adding multi-vitals and inpatient monitoring to its core ambulatory cardiac business, iRhythm is betting that owning the full continuum of care — not just one device category — will be what wins health system contracts going forward.